U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07831122) titled 'Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)' on Sept. 02.
Brief Summary: This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of therapy and/or have refractory to treatment disease.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed Refractory Multiple Myeloma (RRMM)
Intervention:
DRUG: Belamaf
Administered intravenously
BIOLOGICAL: Cevostamab
Administered intravenously
DRUG: Pomalidomide
Admin...